212 related articles for article (PubMed ID: 29970615)
1. An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth.
Tan L; Cho KJ; Neupane P; Capon RJ; Hancock JF
J Biol Chem; 2018 Aug; 293(35):13696-13706. PubMed ID: 29970615
[TBL] [Abstract][Full Text] [Related]
2. Acylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function.
Tan L; Cho KJ; Kattan WE; Garrido CM; Zhou Y; Neupane P; Capon RJ; Hancock JF
J Cell Sci; 2019 Jul; 132(15):. PubMed ID: 31266814
[TBL] [Abstract][Full Text] [Related]
3. Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission.
van der Hoeven D; Cho KJ; Ma X; Chigurupati S; Parton RG; Hancock JF
Mol Cell Biol; 2013 Jan; 33(2):237-51. PubMed ID: 23129805
[TBL] [Abstract][Full Text] [Related]
4. Sphingomyelin Metabolism Is a Regulator of K-Ras Function.
van der Hoeven D; Cho KJ; Zhou Y; Ma X; Chen W; Naji A; Montufar-Solis D; Zuo Y; Kovar SE; Levental KR; Frost JA; van der Hoeven R; Hancock JF
Mol Cell Biol; 2018 Feb; 38(3):. PubMed ID: 29158292
[TBL] [Abstract][Full Text] [Related]
5. Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling.
Garrido CM; Henkels KM; Rehl KM; Liang H; Zhou Y; Gutterman JU; Cho KJ
Sci Rep; 2020 Jun; 10(1):9120. PubMed ID: 32499517
[TBL] [Abstract][Full Text] [Related]
6. Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling.
Kovar SE; Fourman C; Kinstedt C; Williams B; Morris C; Cho KJ; Ketcha DM
Bioorg Med Chem Lett; 2020 Jun; 30(11):127144. PubMed ID: 32276831
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract][Full Text] [Related]
8. KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport.
Schmick M; Vartak N; Papke B; Kovacevic M; Truxius DC; Rossmannek L; Bastiaens PIH
Cell; 2014 Apr; 157(2):459-471. PubMed ID: 24725411
[TBL] [Abstract][Full Text] [Related]
9. Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer.
Kattan WE; Liu J; Montufar-Solis D; Liang H; Brahmendra Barathi B; van der Hoeven R; Zhou Y; Hancock JF
Proc Natl Acad Sci U S A; 2021 Dec; 118(51):. PubMed ID: 34903667
[TBL] [Abstract][Full Text] [Related]
10. AMPK and Endothelial Nitric Oxide Synthase Signaling Regulates K-Ras Plasma Membrane Interactions via Cyclic GMP-Dependent Protein Kinase 2.
Cho KJ; Casteel DE; Prakash P; Tan L; van der Hoeven D; Salim AA; Kim C; Capon RJ; Lacey E; Cunha SR; Gorfe AA; Hancock JF
Mol Cell Biol; 2016 Dec; 36(24):3086-3099. PubMed ID: 27697864
[TBL] [Abstract][Full Text] [Related]
11. Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors.
Wang P; van der Hoeven D; Ye N; Chen H; Liu Z; Ma X; Montufar-Solis D; Rehl KM; Cho KJ; Thapa S; Chen W; van der Hoeven R; Frost JA; Hancock JF; Zhou J
Eur J Med Chem; 2021 May; 217():113381. PubMed ID: 33756124
[TBL] [Abstract][Full Text] [Related]
12. Oligomycins as inhibitors of K-Ras plasma membrane localisation.
Salim AA; Tan L; Huang XC; Cho KJ; Lacey E; Hancock JF; Capon RJ
Org Biomol Chem; 2016 Jan; 14(2):711-715. PubMed ID: 26565618
[TBL] [Abstract][Full Text] [Related]
13. Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function.
Kattan WE; Chen W; Ma X; Lan TH; van der Hoeven D; van der Hoeven R; Hancock JF
Life Sci Alliance; 2019 Oct; 2(5):. PubMed ID: 31451509
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC; Huang PH; Kulp SK; Chen CS
Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of K-Ras plasma membrane localization.
Cho KJ; van der Hoeven D; Hancock JF
Enzymes; 2013; 33 Pt A():249-65. PubMed ID: 25033808
[TBL] [Abstract][Full Text] [Related]
16. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
17. RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling.
Donapaty S; Louis S; Horvath E; Kun J; Sebti SM; Malafa MP
Mol Cancer Ther; 2006 Feb; 5(2):309-16. PubMed ID: 16505104
[TBL] [Abstract][Full Text] [Related]
18. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
[TBL] [Abstract][Full Text] [Related]
19. Rare Streptomyces sp. polyketides as modulators of K-Ras localisation.
Salim AA; Xiao X; Cho KJ; Piggott AM; Lacey E; Hancock JF; Capon RJ
Org Biomol Chem; 2014 Jul; 12(27):4872-8. PubMed ID: 24875924
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
